The Italian biopharma said it had decided to press ahead with the new study after assessing results from 100 patients with TRS in open-label studies who received the glutamate modulator drug as an add-on to their current therapy for more than six months.
The results from Studies 014 and 015 show a statistically significant improvement at week 30 on the Positive and Negative Syndrome Scale (PANSS), with the proportion of patients deemed to have responded to treatment more than doubling in the evenamide group from 16.5% at six weeks.
